Apr. 5 at 1:01 PM
$SLS Sunday Math: Why
$SLS is the Biggest Steal in Biotech 📈💣
Let’s talk "Failure Floors." Gilead paid
$5B for Magrolimab—a Phase 1/2 asset that the FDA eventually SHUT DOWN for safety. If a failed drug is the
$5B baseline, why is our safe, Phase 3-ready GPS valued at pennies?
Then there’s Merck dropping
$6B+ on Phase 1 assets that haven’t even cleared safety hurdles. A de-risked Phase 2/3 pipeline like ours is statistically worth DOUBLE that entry point.
The Ovarian Gap is Real: AbbVie paid
$10B for Elahere. Our Phase 2 results are ALREADY outperforming those benchmarks.
$12B isn’t a dream; it’s the next logical step.
The Price Targets:
$6B Floor (The "Joker" Price): ~
$33/share
$12B Target (Fair Value): ~
$67/share
$20B "Atomic Bomb" (Solid Tumor Sweep): ~
$111/share
With Friday's "Atomic Bomb" news confirming we are a GO for Lung, Pancreatic, and Ovarian, we are worth more now than ever. The market is slow, but the math doesn't lie! 🚀🎯 #SLS
$PFE $MRK $LILLY $ABVE
